Expand RGNT Menu
RGNT MENU

RGNT Latest Press Releases

-- April 16, 2026 --

Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon ACCESS Newswire 8:30 AM

-- March 17, 2026 --

Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% ACCESS Newswire 8:30 AM

-- February 24, 2026 --

Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update ACCESS Newswire 4:15 PM

-- February 19, 2026 --

Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair ACCESS Newswire 8:30 AM

-- February 17, 2026 --

Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs ACCESS Newswire 8:30 AM

-- February 4, 2026 --

Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial ACCESS Newswire 8:33 AM

-- January 29, 2026 --

Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S. ACCESS Newswire 8:33 AM

-- January 20, 2026 --

Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method ACCESS Newswire 8:33 AM

-- January 6, 2026 --

Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation ACCESS Newswire 8:21 AM

-- December 18, 2025 --

Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC ACCESS Newswire 8:35 AM

-- December 5, 2025 --

Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering Globe Newswire 4:10 PM
Market Data Delayed 15 Minutes